An aggressive clinical course of polycythemia vera with coexisting complications: a case report

Authors

  • Kshitij H. Kanuga Smt. N.H.L Municipal Medical College, Ahmedabad, Gujarat, India
  • Anoushka Arora Smt. N.H.L Municipal Medical College, Ahmedabad, Gujarat, India
  • Yashraj Dhruva SVPIMR

DOI:

https://doi.org/10.18203/2320-6012.ijrms20253642

Keywords:

Polycythemia vera, Hyper viscosity, EPO

Abstract

Polycythemia vera (PV) is a myeloproliferative disorder characterized by rapid proliferation of red blood cells. It may present with symptoms of hyper viscosity. Complication of thrombosis is well recognized, but its rapid progress and coexistence of involvement of various organ sites simultaneously are not seen as often. We present a case of a 40-year-old female who was incidentally diagnosed with PV due to her presentation with extrahepatic portal venous obstruction (EHPVO). Her elevated platelet count prompted a bone marrow biopsy, leading to the finding of Janus kinase-2 (JAK2)-positive PV. Her condition rapidly progressed to decompensated chronic liver disease, likely triggered by the portal hypertension due to EHPVO. This was further complicated by her PV progressing to myelofibrosis, a rare complication of PV. This progression typically occurs after 10-15 years of diagnosis, but in this case, it was seen within 3 years, demonstrating the rapid course of her disease. This case is noteworthy for how differently PV can present. It highlights the importance of investigating patients for underlying blood malignancies when they present with clots without any identifiable cause. It also sheds light on how fast this disease can progress and shows the importance of early diagnosis and appropriate management to prevent several complications associated.

 

Metrics

Metrics Loading ...

References

Pillai AA, Fazal S, Mukkamalla SKR, Babiker HM. Polycythemia. In: StatPearls. StatPearls Publishing. 2025.

Ashavaid TF, Todur SP, Dherai AJ. Establishment of reference intervals in Indian population. Indian J Clin Biochem. 2005;20(2):110-8. DOI: https://doi.org/10.1007/BF02867409

Billett HH. Hemoglobin and Hematocrit. In: Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Butterworths. 1990.

Lu X, Chang R. Polycythemia Vera. In: StatPearls. StatPearls Publishing. 2025.

James C, Ugo V, Le Couédic J-P, Judith S, François D, Catherine L, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8. DOI: https://doi.org/10.1038/nature03546

Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-9. DOI: https://doi.org/10.1182/blood-2007-12-128454

Metzger PB, Costa KR, Silva SLE, Valter RDS, Vinicius N, Murilo QBF, et al. Budd-Chiari syndrome due to hepatic venous web outflow obstruction: percutaneous treatment with balloon angioplasty. J vasc bras. 2021;20:e20200133.

Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921-8. DOI: https://doi.org/10.1182/blood-2011-09-376517

Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801-21. DOI: https://doi.org/10.1002/ajh.26857

Kiladjian J-J, Gardin C, Renoux M, Bruno F, Bernard J-F. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J. 2003;4(3):198-207. DOI: https://doi.org/10.1038/sj.thj.6200250

Gleitz HFE, Benabid A, Schneider RK. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms. Curr Opin Hematol. 2021;28(5):364-71. DOI: https://doi.org/10.1097/MOH.0000000000000669

Beleva EA. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype. Int J Mol Sci. 2023;24(21):15717. DOI: https://doi.org/10.3390/ijms242115717

Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11):e366. DOI: https://doi.org/10.1038/bcj.2015.95

Downloads

Published

2025-10-30

How to Cite

Kanuga, K. H., Arora, A., & Dhruva, Y. (2025). An aggressive clinical course of polycythemia vera with coexisting complications: a case report. International Journal of Research in Medical Sciences, 13(11), 5008–5010. https://doi.org/10.18203/2320-6012.ijrms20253642

Issue

Section

Case Reports